Biorithm to drive true clinical improvements in the detection of fetal distress and early warning systems

“We need to bring pregnancy care into the 21st century, focusing on how we can utilise data to improve the pregnancy journey.”

Amrish Nair, Founder, Biorithm

Register Interest

Problem

High risk pregnant women required to travel to the clinic or hospital for frequent routine monitoring which leads to:

• Increased costs for payers
• Burdened outpatient clinics
• Patient inconvenience
• Increased infection risk

Solution

In light of the new normal that 2020 has descended upon the world, new mindsets have to be adopted especially with regards to healthcare. Biorithm developed a system called Femom that is intended for remote monitoring of maternal and fetal physiological parameters which fits into the paradigm of shifting healthcare beyond the walls of a hospital. It includes a non-invasive fetal monitor that monitors fetal heart rate (FHR), maternal heart rate (MHR), and uterine activity (UA) in the prenatal period.

The system is intended for pregnant patients. It may be used in the home environment or a clinical setting such as hospitals or clinics. The fetal monitor is indicated for use in patients with singleton pregnancies from 28 weeks of gestation onwards.

The objective of this solution is to improve health outcomes while reducing costs and minimizing risks.

Competitve Edge

Biorithm’s competitive advantage can be summarized in 4 main points:

• Femom’s comprehensive feature set including fetal and maternal vitals, BP, Glucose and digital questionnaires, which have been an interesting feature for clinicians.
• Access to the correct KOLs who could help the company access markets on a national level.
• Biorithm’s research is taking a focused path as compared to general machine learning approaches taken by other companies.
• Continuity of care is an increasingly mentioned word in departments who view women’s health as a continuum rather than separated into various specialties. This involves management of pre pregnancy co-morbidities, multidisciplinary care and post-partum care.

Team

The co-founding team has worked together since 2012 at Nanyang Technological University and the full-time team come from a variety of backgrounds including academia, IP commercialisation, software and technology and business administration. The bond that unites the team is the belief that Biorithm’s work will lead to an improvement in care for women and children globally.

Our team is very diverse and comes from 4 different continents: Asia, Africa, Europe, and North America, and from diverse backgrounds such as clinicians, PhDs , engineers, and MBAs.

Raise

Biorithm is raising $400k out of a total raise of $1M for a bridge round. $600k has been raised through angel investors including existing shareholders.The raise will be done through a SAFE convertible note which will have a cap of 12M USD and a 20% discount off the next priced investment round, whichever is lower. The bridge would enable Biorithm to complete pilot manufacturing and clinical studies, both scientific and regulatory.

Ambitions

Biorithm intends to be a platform for monitoring technologies in women’s health. As a first step, Bioirthm intends to fill the void of remote monitoring in pregnancy in Australia, UK, Europe and the US, and as part of a first wave of remote pregnancy monitoring companies, alter the way women are clinically monitored during these precious nine months. Equipped with this new data, Biorithm intends to drive true clinical improvements in detection of fetal distress, early warning systems and ultimately to deliver new knowledge and tools in the field of fetal origin of disease and population health management.

The next steps would be to tackle adjacent spaces such as maternal mental health and post-natal monitoring.

Highlights

• Across 2500 start-ups globally, Biorithm was selected for the global Philips Healthworks program in 2019 and was the only one of 3 companies selected from Asia. Through the program, Biorithm engaged with internal stakeholders and are in talk to form partnerships that would help break barriers in terms of market entry and adoption.
• Biorithm was also featured in several news pieces on SBS (Australia) and in Singapore featuring collaborations with Monash University and National University Hospital Singapore.

Register Interest